Latest Asx News

High Peak Royalties reported robust cash receipts and successfully repaid its Macquarie Bank facility in the December 2024 quarter, while advancing its geothermal exploration strategy in South Australia.

Dateline Resources Limited’s latest quarterly report reveals a sharp decline in cash reserves, underscoring the company’s urgent need to secure additional funding to sustain its exploration activities.

Nanoveu Limited reports strong momentum in its EyeFly3D technology with a significant purchase order and launches an AI-powered app, while advancing its strategic acquisition of semiconductor innovator EMASS.

NT Minerals reports exceptional copper assay results from its Twin Peaks Project in Western Australia, alongside strategic option agreements that could reshape its Northern Territory portfolio.

Admiralty Resources NL has marked a significant production milestone at its Mariposa Iron Ore Project in Chile, securing a sales agreement for 80,000 tonnes of iron ore amid ongoing operational and environmental progress.

Atomos Limited reported a 7% increase in Q2 FY25 sales driven by its core Shinobi II product, but faced margin pressures due to discounting and competitive pricing. The company is finalizing a cost restructure and reviewing funding options to support future growth.

Toro Energy reports steady progress in its Wiluna Uranium Project with updated resource estimates and ongoing native title consultations, positioning itself to capitalize on improving uranium market conditions.

Artemis Resources has secured $4 million in funding to advance drilling at its Karratha Gold Project, following promising high-grade surface sampling and a strategic leadership appointment.

AdNeo reported a standout quarter with record new sales led by its US-based Art of Mentoring division and significant operational cost reductions, positioning the company for growth through strategic acquisitions.

Cadoux Limited reports significant progress in its high purity alumina and Minhub rare earths projects, alongside robust environmental, social, and governance initiatives.

Recce Pharmaceuticals has gained key regulatory and ethics approvals for its Phase 3 clinical trial in Indonesia and completed patient dosing for its Phase II trial, while securing a substantial A$6.75 million R&D tax rebate to bolster its financial position.

Merino & Co’s successful IPO has injected $6.35 million into the company, enabling a strategic expansion of manufacturing capacity and securing a new facility in Western Australia. The company is now poised to scale globally with automated production and enhanced distribution capabilities.